Skip to main content
Quest Diagnostics

Myotonic Dystrophy Type 1 Genetic Testing in Over 30,000 Patients: Does Size Really Matter As We Get Older?

ACMG Annual Clinical Genetics Meeting, 2024

American College of Medical Genetics and Genomics

Toronto, Canada, March 12-16, 2024

Poster presentation: Myotonic Dystrophy Type 1 Genetic Testing in Over 30,000 Patients: Does Size Really Matter As We Get Older?

Authors: Powis Z, Liaquat K, Meservey M, Louie JZ, Batish SD

Specialty: Genetics, Neurology

Related content

Publication
Prevalence of RPGR-Mediated Retinal Dystrophy in an Unselected Cohort of Over 5000 Patients
Publication
Targeted Sequencing and In Vitro Splice Assays Shed Light on ABCA4-Associated Retinopathies Missing Heritability
Conference Presentation
Genetic findings in a large cohort of retinal dystrophy patients: implications for gene-specific treatments and clinical trials
Conference Presentation
Characterization of molecular diagnosis of inherited retinal disease within a large pediatric cohort undergoing comprehensive retinal dystrophy panel next-generation sequencing analysis

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.